Noteworthy lectures focus on cutting edge therapeutics

Article
Conference|San Antonio Breast Cancer Symposium (SABCS)

Oncology NEWS International guest editor Dr. Andrew D. Seidman recommends SABCS 2008 lectures on modern molecular science, molecular profiling, and the American Association of Cancer Research distinguished lectureship in breast cancer research.

SAN ANTONIO-Oncology NEWS International guest editor Dr. Andrew D. Seidman recommends the following SABCS 2008 lectures:

  • William L. McGuire memorial lecture What is cancer? How modern molecular science is challenging traditional views," given by Larry Norton, MD, Memorial Sloan-Kettering Cancer Center, New York



  • Mini-symposium "Molecular Profiling for guiding therapeutic decisions," moderated by Suzanne A.W. Fuqua, PhD, from Baylor College of Medicine, Houston, and Laura van't Veer, PhD, Netherlands Cancer Institute, Amsterdam. Topics: RNA, personalized medicine, predictors of response to adjuvant therapy.



  • American Association of Cancer Research (AACR) distinguished lectureship in breast cancer research Titled "Deconstructing metastasis," the lecture will be delivered by Joan Massagu, PhD, of Memorial Sloan-Kettering Cancer Center, New York

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
3 experts in this video
3 experts in this video
Related Content
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer

87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer

Hope S. Rugo, MD;Sara M. Tolaney, MD, MPH;Nancy Chan;Erika P. Hamilton, MD;Eva Ciruelos;Ji-Yeon Kim;Elena López-Miranda;Elia Seguí;Neelima Vidula, MD;Joyce O’Shaughnessy, MD;Guiseppe Curigliano;Javier Cortés, MD;Alessandro Di Sanzo;Paula Muñoz Romero;Bartomeu Piza Vallespir;Manuel Dominguez;Kathy Puyana Theall;Alessandro Paoli;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
April 24th 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

BOLDSCIENCE;Pedram Razavi;Judith Balmaña;Stephen Luen;Mario Campone;Laura Cortesi;Norikazu Masuda;Kyong Hwa Park;Qingyuan Zhang;Emily Nizialek;Cathy Qi;Karen Cui;Sibylle Loibl;Mark Robson, MD;Filipa Lynce
April 22nd 2025
Article
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer

T-DXd With Pertuzumab Improves PFS in HER2+ Metastatic Breast Cancer

Tim Cortese
April 21st 2025
Article

Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

Roman Fabbricatore
April 21st 2025
Article

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.